Biosimilar developer Sandoz announced today that it has entered into a global partnership with India-based Biocon to develop, manufacture, and commercialize multiple biosimilars targeting immunology and oncology indications.
Biosimilar developer Sandoz announced today that it has entered into a global partnership with India-based Biocon to develop, manufacture, and commercialize multiple biosimilars targeting immunology and oncology indications.
Under the agreement, the companies will share responsibility for end-to-end development, manufacturing, and regulatory approvals for the products in question, and will share costs and profits. Sandoz will lead commercialization of approved biosimilars in North America and the European Union, while Biocon will commercialize the drugs in the rest of the world.
“Today’s announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future,” said Richard Francis, CEO of Sandoz, in a statement. “Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics.”
Chairperson and managing director of Biocon, Kiran Mazumdar-Shaw, added, “This synergistic partnership will enable us to scale up our capabilities for an end-to-end play in the global biosimilars space.”
The agreement with Sandoz forms Biocon’s second partnership seeking to bring its biosimilars to the US and EU markets; Biocon successfully partnered with Mylan on a trastuzumab biosimilar, Ogivri, approved by the FDA in December 2017. Last week, at the 36th Annual J.P. Morgan Healthcare Conference, Rajiv Malik, company president of Mylan, hinted that Biocon—Mylan’s pegfilgrastim biosimilar could gain FDA approval by the middle of 2018. Both the trastuzumab and pegfilgrastim products are also under European regulatory review.
News of the Sandoz—Biocon partnership comes just days after Sandoz announced that the FDA has accepted for review its Biologics License Application (BLA) for a proposed adalimumab (Humira) biosimilar. The drug maker has already received FDA’s nod for its etanercept biosimilar (which will be marketed in the United States as Erelzi, though no launch date has been made public) and its filgrastim biosimilar (Zarxio). The FDA is currently considering a BLA for Sandoz’s rituximab biosimilar, and the drug maker reports that it will refile its BLA for a pegfilgrastim biosimilar in 2019.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.